Shares of cancer detection and cancer therapy solutions provider iCAD (NASDAQ:ICAD) are in the green today on the back of its development and commercialization deal with Google (NASDAQ:GOOGL)(NASDAQ:GOOG) .
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Under the agreement, Google Health’s AI technology will be integrated with ICAD’s breast imaging AI solutions. The two companies will also work on enhancing ICAD’s solutions for mammography and expanding access to the technology.
Further, ICAD will utilize the licensed technology from Google to enhance its 3D and 2D AI algorithms and will bring the developed products to market.
Despite today’s price gains, ICAD shares are still down nearly 76% over the past year. The Street, in the meantime, has a Strong Buy consensus rating on the stock alongside an average price target of $5.20.
Read full Disclosure